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Epigenetic pathways help control the expression of genes. In cancer and other diseases, aberrant silencing or overexpression of
genes, such as those that control cell growth, can greatly contribute to pathogenesis. Access to these genes by the transcriptional
machinery is largely mediated by chemical modiﬁcations of DNA or histones, which are controlled by epigenetic enzymes,
making these enzymes attractive targets for drug discovery. Here we describe the characterization of a locus derepression assay,
a ﬂuorescence-based mammalian cellular system which was used to screen the NCI structural diversity library for novel epigenetic
modulators using an automated imaging platform. Four structurally unique compounds were uncovered that, when further
investigated, showed distinct activities. These compounds block the viability of lung cancer and melanoma cells, prevent cell
cycle progression, and/or inhibit histone deacetylase activity, altering levels of cellular histone acetylation.
1.Introduction
Pathologies such as human cancer result largely from the
inappropriate silencing or activation of genes. It is well
established that gene expression can be partly controlled
by modulating the access of the transcriptional machinery
to target genes through chemical modiﬁcations of DNA
sequences or histones, the proteins that package DNA. These
modiﬁcations are mediated by cellular enzymes, including
DNA methyltransferases, histone acetyl transferases (HATs),
histone deacetylases (HDACs), histone methyltransferases
(HMTs), histone demethylases, and histone kinases. Epi-
genetic enzymes function during development, helping
orchestrate complex transcriptional programs that control
diﬀerentiation pathways. During adult life, these enzymes
continue to inﬂuence transcription by maintaining tissue-
speciﬁc epigenetic and transcriptional patterns as well
as by acting as coregulators for transcription factors. In
many cancers, the regulation of transcriptional processes is
altered partly because of the abnormal expression and/or
function of epigenetic enzymes resulting in the silencing
of tumor suppressor genes or in equivalent events that
lead to unchecked cellular growth [1]. Indeed, it has been
estimated that epigenetic changes are at least ten to forty
times more frequent in cancers than genetic mutations [1–
3]. Furthermore, speciﬁc mutations in HATs and HMTs have
been found in relation to the cancer phenotype, suggesting
them as potential targets for therapy [4]. Thus, eﬀective
treatment of cancer will, at least in part, necessitate the
chemical targeting of the cancer epigenome.
Overthe lasttwo decades, drugshave been identiﬁed that
modulate the pathways mediated by a subset of epigenetic
enzymes.Becausecancercellsoftenhaveabnormallysilenced
tumor suppressor genes or overexpressed oncogenes, medi-
ated by epigenetic pathways, these drugs have been studied
in preclinical contexts. Of the known compounds, however,
only a few have shown success in clinical settings, with
toxicities observed for most other compounds due to their
global, unspeciﬁc eﬀects on cell function [5–9]. This has
led to new drug discovery and drug development eﬀorts
at industrial and academic laboratories over the last few
years. These programs have used cell-based, in vitro, in silico,2 Journal of Biomedicine and Biotechnology
or yeast systems to identify novel drugs or have developed
second-generationcompoundsstructurallyrelatedtoalready
known inhibitors [10–18].
Altogether, more recent studies have yielded several
new compounds that target epigenetic enzymes, primarily
histone deacetylase family members and enzymes that mod-
ulate methylation [15, 19–22]. Some of these compounds
oﬀer limited beneﬁt over existing drugs, since they are
structurally closely related to known inhibitors of epigenetic
enzymes, are unspeciﬁc, or lack substantial in vivo activity,
due at least in part to limitations in drug screen design.
To date, there are only a few epigenetic drugs approved by
the FDA, including: 5-azacytidine and its deoxy derivative
decitabine, both DNA methyltransferase inhibitors used for
the treatment of myelodysplastic syndromes, vorinostat, and
recentlyromidepsin,HDACinhibitorsusedforthetreatment
of cutaneous T cell lymphoma [23–26]. There is, therefore,
a persistent need to increase the number and diversity of
available anticancer epigenetic modulators and to develop
innovative, improved approaches for drug discovery.
Because screens that use in vitro or in silico approaches
mayleadtohitsthatprovetobetoxic,insoluble,orineﬃcient
when taken to the in vivo setting, using systems in which
drugs are directly tested in cells, as was done for some of
the original HDAC inhibitors [10, 11, 18], can save time and
eﬀort on followup studies of drugs that are only eﬀective
in vitro or would require substantial chemical optimization.
Here, we report the characterization and use of a cell-based
assay in which a locus containing an easily quantiﬁable
marker, green ﬂuorescent protein (GFP), is epigenetically
silenced, and derepressed chemically by known epigenetic
modulators targeting both histone acetylation and DNA
methylation. We have now successfully used this system, the
Locus Derepression assay (LDR) [27, 28], to screen the NCI’s
structural diversity library to identify novel compounds with
epigenetic activity. Four conﬁrmed hits from the screen were
further investigated for their anticancer properties and their
ability to inhibit histone deactylases. We found that two of
our hits potently blocked the viability of both lung cancer
and melanoma cells and that one of them caused cancer
cells to accumulate in the G2/M phase, preventing cell cycle
progression. A third hit inhibited deacetylase activity in vitro
and in cells, but on its own had little toxicity, while a fourth
compound selectively inhibited the viability of melanoma
cells compared to lung cancer cells.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Dulbecco’s modiﬁcation of
eagle’s medium (DMEM), Dulbecco’s phosphate-buﬀered
saline (DPBS), and G418 were purchased from Mediat-
ech (Manassas, VA). The penicillin/streptomycin solution,
trypsin-EDTA, and 37% formaldehyde were purchased from
Sigma-Aldrich (St. Louis, MO). Hoechst 33342 was obtained
from Invitrogen (Carlsbad, California). Trichostatin A and
apicidin were obtained from Alexis Biochemicals, depsipep-
tide was a generous gift from Dr. David Schrump and 5-aza-
2 deoxycytidine and sodium butyrate were purchased from
Sigma/Aldrich. Hit compounds for followup were provided
by the Drug Synthesis and Chemistry Branch, DTP, NCI.
All drugs were dissolved in dimethyl sulfoxide (DMSO) and
stored at −20◦C.
2.2. Cell Culture and Materials. LDR cells were grown in
DMEM media with 10% heat inactivated FBS and supple-
ments, as previously described [29]. The C127 cells were
grown in DMEM supplemented with 100U/mL penicillin,
100µg/mL streptomycin, and 10% charcoal/dextran-treated
FBS. Cells were cultured in a humidiﬁed incubator at a 37◦C,
5% CO2, and 95% air environment.
2.3. Drug Screen. LDR cells were plated into 96-well Nunc
glass-bottom black plates at 8,000cells/well and cultured in
complete media at 37◦C, 5% CO2, and 95% air overnight.
DMSO (0.5%) was used for the negative control and
25mM sodium butyrate was used as the positive control.
Twenty-four hours after seeding the cells into assay plates,
cells were treated with the structural diversity chemical
library (4µM ﬁnal). After a 24 hour treatment with the
chemical library, the assay plates were subjected to ﬁxation
with 4% formaldehyde for 45 minutes. After ﬁxation, the
assay plates were washed 5 times with 100µL of DPBS.
The plates were stained with 0.3µg/mL Hoechst 33342 in
DPBS overnight at 4◦C. The next day, assay plates were
washed twice with 100µL of DPBS, and the plates were
sealed with aluminum sealing tape and were barcoded
with a Velocity-11 VCode Bar Code Label Print and Apply
Station (Menlo Park, CA). Images were acquired using
the Discovery-1 imaging system, at 20X, 4 sites per well,
30ms exposure for Hoechst 33342, and 600ms exposure for
GFP, and they were processed with Metamorph software.
Hits were identiﬁed by manual examination of images for
GFP expression. Hit compounds were cherry picked and
subjected to quadruplicate testing in the LDR cell line
and in the C127 parental cell line to conﬁrm activity and
eliminate false positive results due to ﬂuorescent com-
pounds.
2.4. Fluorescence Microscopy. For followup experiments,
LDR cells were plated on four-well chambered glass slides
(Lab-TekII, Nunc) at a density of 15,000 cells per well,
treated with drug and incubated for 24 hours in 5% CO2
at 37◦C, and imaged either on a Nikon Eclipse TE2000-
U ﬂuorescence microscope equipped with a CCD Roper
camera, an Olympus 1 × 70 system equipped with a
PhotometricscameraoronaCARVMetamorphsystemwith
an Orca II CCD camera. Metamorph software was used to
process the images.
2.5. GFP Quantiﬁcation. Fluorescent Activated Cell Sorting
(FACS) was used to quantify GFP levels in LDR cells after
various drug treatments in dose response studies. Brieﬂy,
cells were collected and pelleted, washed in PBS, and then
resuspended in PBS at 100,000cells/mL and subjected to
analysis in BD FACSCalibur sorter. Data was analyzed using
FlowJo software. Uninduced and vehicle treated cells were
used as a negative control for gating.Journal of Biomedicine and Biotechnology 3
2.6. Cell Viability Assays. Human cancer cell lines were
plated in RPMI media with 5% heat-inactivated FBS, at
2000–4000 cells per well of 96-well ﬂat-bottom plates.
The next day, cells were treated with compounds with
maximum concentrations ranging between 15µMa n d5µM
and allowed to incubate for 4 days in 5% CO2 at 37◦C.
Cells were then treated with MTS reagent and absorbance
measured according to the company’s protocol (CellTiter 96
AQueous Nonradioactive Cell Proliferation Assay, Promega).
2.7. Cell Cycle Analysis. H358 cells were treated with 1µM
5-aza, 200nM TSA, 5µM NSC-159631, or DMSO and
incubated for 24 hours in 5% CO2 at 37◦C. Cells were
trypsinized and stored in 75% ethanol at −20◦C and later
washed in PBS and suspended in propidium iodide staining
buﬀer (1x PBS, 0.1% Triton X-100, 0.5mM EDTA, 50µg/mL
DNAse-free RNase, and 0.05mg/mL propidium iodide).
Samples were then analyzed in the UT Southwestern FACs
core using a BD FACSCalibur sorter. Data was analyzed with
FlowJo software.
2.8. HDAC Assays. HDAC activity was analyzed using the
HDAC Assay Kit from Millipore/Upstate (17-356). Brieﬂy,
nuclear extract from Baf3 cells or puriﬁed, recombinant
HDAC1 (Millipore/Upstate) was allowed to incubate with
the ﬂuorometric HDAC substrate according to the manu-
facturer’s protocol. In a secondary activator reaction, the
ﬂuorophore is only cleaved from the deacetylated substrate,
allowing for quantiﬁcation. Fluorescence was quantiﬁed on a
FLUOstar-Optima or a FLUOstar Omega plate reader (BMG
Biosciences).
2.9. Western Blot Analysis. H358 cells were treated with
10µM NSC-22206, 200nM TSA, 0.5µM NSC-159631, or
DMSO for 24 hours, and protein was extracted using a
lysis buﬀer (50mM NaCl, 1mM EDTA, 2.5mM Tris pH
7.4, 0.1% SDS, and 1% NP-40). Protein was quantiﬁed
and equal amounts of samples were run on 4%–12% SDS
acrylamide gradient gels and transferred to nitrocellulose
membranes. Membranes were incubated overnight with
0.05µg/mL polyclonal rabbit anti-acetyl-Histone 3 antibody
(Millipore/Upstate 06-599). Blots were washed and rein-
cubated with anti-actin primary antibody (Santa Cruz no.
1616). Bands were imaged using enhanced chemilumines-
cence reagents from Thermo Scientiﬁc. For Supplementary
Figure 2B available at doi: 10.1155/2011/868095 , the addi-
tional antibodies used were as follows: HDAC1 (Aﬃnity
Bioreagents PA1-860), acetylated tubulin (Sigma T6793) and
H3K9me3 (Millipore 07-523).
3. Results andDiscussion
3.1. Development of Cell-Based GFP Assay. To screen for
epigenetic modulators, we developed a cell-based assay,
consisting of C127 mouse mammary adenocarcinoma cells
stably expressing a GFP construct linked to a portion of the
estrogenreceptorligandbindingdomain,drivenbytheCMV
promoter, which is susceptible to epigenetic repression. On a
separate plasmid, the gene for neomycin resistance was also
introduced. We selected cells that were neomycin resistant
but whose GFP expression was constitutively silenced. After
clonal expansion, GFP expression remained repressed. Upon
treatment of cells with epigenetic modulators, we expected
GFP production (Figure 1). The use of GFP allows for easy
and automatic detection, applicable to both low and high
throughput screening applications. The detailed design of
this cell-based assay, named the locus derepression or LDR
assay, has been described elsewhere [27, 28].
3.2. Characterization of the LDR Assay. To determine if the
GFP construct in LDR cells was under epigenetic regulation
and if so, what classes of epigenetic modulators would
derepress the locus, LDR cells were treated with diﬀer-
ent structural classes of HDAC inhibitors and with DNA
methyltransferaseinhibitors.Thecellswerethenanalyzedfor
GFP expression by visualization with a ﬂuorescent micro-
scope (Figure 2(a)), evaluated in dose-response experiments
(Figure 2(b))and/orquantiﬁedbyﬂuorescence-activatedcell
sorting (FACS) (Figure 2(c)). Class I/II HDAC inhibitor
trichostatin A (TSA), a hydroxamic acid, was added to the
cells at a concentration of 165nM, and GFP expression
was measured. Treating cells with increasing concentrations
of TSA ranging from 16nM to 827nM demonstrated that
the induction of GFP in LDR cells was dose dependent
(Figure 2(b)). The short chain fatty acid butyrate, also a
Class I/II HDAC inhibitor, was able to induce expression of
GFP as measured by both microscopy (Figure 2(a), middle
left panel) and FACS (Figure 2(c)). Butyrate induction of
GFP expression was also seen to be dose dependent when
tested with concentrations ranging from 1mM to 100mM
(Figure 2(b)). Similar results were observed with apicidin, a
cyclic tetrapeptide HDAC inhibitor. Cells treated with 5µM
apicidin had a signiﬁcantly increased green ﬂuorescent pop-
ulation, as shown by FACS (Figure 2(c)). Apicidin also dere-
pressed the GFP construct in a dose-dependent manner, at
concentrations between 0.1µMa n d1 0µM( Figure 2(b)). We
also evaluated a Class I-speciﬁc HDAC inhibitor, the cyclic
depsipeptide FR901228 also known as simply depsipeptide
or romidepsin, which potently induced GFP production at
25ng/mL (Figure 2(a), bottom left panel). Taken together,
these results demonstrate that the GFP construct in LDR
cells is under epigenetic regulation which can be overcome
by any structural type of HDAC inhibitor. As expected from
their functionally distinct roles, inhibition of class 3 HDACs
by nicotinamide had no eﬀect on GFP production although
Sirt 1 enzymatic activity was markedly diminished in vitro
(data not shown). Interestingly, BIX-01294, an inhibitor of
G9a histone methyltransferase [15], did not induce GFP
expression at up to 10µM doses over a two day exposure,
suggesting that histone methylation by G9a is not required
for CMV silencing in LDR cells.
To test whether the silenced locus was also under the
control of DNA methylation (which was possible due to the
presence of a large CpG island on the CMV promoter), we
measured the eﬀects of a DNA methyltransferase inhibitor,
5-aza-2 deoxycytidine (5-aza) and found that it too was
able to induce GFP expression (Figure 2(a),b o t t o mr i g h t
panel). Similar results were obtained with 5-aza-cytidine.4 Journal of Biomedicine and Biotechnology
CMV
GFP
Neor
− epigenetic modulator + epigenetic modulator
Select for GFP-negative,
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Figure 1: Schematic representation of the process of creating transgenic mouse mammary adenocarcinoma cells (locus derepression assay
cellsorLDR)[29].AconstructcontainingtheGFPgenelinkedtotheestrogenreceptorligand-bindingdomain,drivenbytheCMVpromoter
and a neomycin resistance marker, was stably transfected into cells. GFP negative cells, stably expressing the neomycin resistant gene, were
selected. With the addition of an epigenetic modulator, such as an HDAC inhibitor or a DNA methyltransferase inhibitor, the cells express
GFP and can be visualized by ﬂuorescence microscopy. When cells are then treated with estradiol, the GFP fusion protein translocates to the
nucleus.
However, other molecules, such as general transcriptional
activators including hormones, steroids, and amino acids,
were incapable of inducing GFP production, as were protea-
some inhibitors or general stress conditions such as hypoxia
and starvation (data not shown). These experiments show
that the GFP construct is, indeed, silenced epigenetically and
can be derepressed by inhibiting HDAC as well as DNA
methyltransferasepathways(andpotentially otherepigenetic
cascades), emphasizing the assay’s utility in ﬁnding novel
epigenetic modulators.
To conﬁrm that GFP expression induced by drug treat-
ment was dependent upon de novo transcription of the
locus and did not, for example, involve increased stability
or translation of an already transcribed message, we mea-
sured the eﬀects of actinomycin-D on GFP production. We
cotreatedLDRcellswith200nMTSAor25nMdepsipeptide,
in the presence or absence of 0.5µg/mL actinomycin-D, a
known inhibitor of transcription. Actinomycin-D prevented
the production of GFP in response to both TSA (Figure 3(a)
and 3(b)) and depsipeptide (Figures 3(c) and 3(d)). This
conﬁrms that the expression of the silenced locus requires
new transcription, engaging the pathways the assay was
designed to exploit.
3.3. Drug Screens Using the LDR Assay and Characteri-
zation of Hit Molecules. To adapt LDR cells for use in
screening applications, we ﬁrst isolated a subset of the
most responsive transgenic cells, which showed a 70%–90%
response to 25mM butyrate (Figure 4(a)) and expanded
them clonally. These cells grew well in 96-well plate format
and produced robust GFP signal (Figure 4(b)). We used
these LDR cells for drug screens to identify potential novel
epigenetic modulators that would turn on the expression
of GFP in cells. Cells were plated in 96-well plates, grown
overnight,andtreatedfor24hourswith4µMconcentrations
of compounds from the NCI structural diversity library,
which was chosen in order to maximally query chemical
space for new active structures. After ﬁxation, cells were
visualized using a Discovery-1 automated ﬂuorescent micro-
scope which captured two-by- two frames in each well
(Figure 4(b)).HitsweremanuallyscoredforGFPexpression,
and of the 2,080 compounds screened, 71 of them were
primary hits. However, after eliminating the autoﬂuorescent
compounds by counter screening on parental C127 cells, and
retesting the remaining hits through cherry picking, there
were 4 conﬁrmed hits which were followed up (Table 1).
T h e s ec o n ﬁ r m e dh i t sw e r ev a l i d a t e da tt h ep r o t e i nl e v e lb y
measurements of GFP protein translocation in response to
estradiol,makinguseoftheestrogenreceptorligand-binding
domain which is expressed in LDR cells downstream of GFP
on the same construct (see Supplementary Figure 1) [28].
The hits from this library are not only structurally
distinct from each other, but also from other known
HDAC and DNA methyltransferase inhibitors, providing
structural diversity to this chemical class. To analyze if
these compounds were active at a single dose or showedJournal of Biomedicine and Biotechnology 5
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Figure 2: Characterization of cell-based LDR assay. (a) Visualization of GFP expression in cells treated with various known epigenetic
modulators. TSA, butyrate, apicidin, and depsipeptide are HDAC inhibitors and 5-aza-deoxycytidine is a DNA methyltransferase inhibitor.
(b) Cells exhibit dose-dependent GFP expression in response to HDAC inhibitors. (c) FACS analysis reveals an increase in number of cells
expressing GFP when treated with butyrate or apicidin, compared to untreated cells.
dose responsiveness, two of our hits were analyzed in a
concentration series. Secalonic acid D (NSC-159631) [30],
was added in concentrations ranging between 10nM and
10µM, and NSC-22225 was tested between 500nM and
10µM. GFP induction in response to secalonic acid D was
strongly dose dependent showing a half-maximal activation
between 1–5µM( Figure 5(a)), while NSC-22225 showed a
weaker but nonetheless clear dose dependence (Figure 5(b),
note toxicity to mouse LDR cells at 10µM). A search for
compounds structurally related to our hits, yielded NSC-
22206 and NSC-22214, which vary from NSC-22225 only
in the nature of the metal salt. As expected, these related
molecules also induced GFP expression in LDR cells but had
aslightlylowerpotencythantheprimaryhit(Figure 5(c)and
data not shown).
Epigenetic modulators have been postulated to have
anticancer properties because they can mediate the
reexpression of silenced tumor suppressor genes and in a
manner, that is not yet fully understood, can block cell cycle
progression [1, 18, 22, 31, 32]. To evaluate the ability of
LDR hits to inhibit the viability of human cancer cells, we
performedstandardMTSassaysonnonsmallcelllungcancer
and melanoma cells [33, 34]. Table 2 shows the average IC50
values obtained in 1–5 experiments each done with 8
replicates. While NSC-22225 and its related compound were
incapable of blocking human cancer cell growth, other hits
inhibited cancercellviability with IC50’s ranging from 90nM
to 9µM. Interestingly, while NSC-150117 and secalonic acid
Dw e r ee ﬀective against both lung cancer and melanoma
cells of uveal origin, NSC-693322 preferentially targeted
melanomacells,suggestingthatthiscompoundmayinterfere
with a signaling cascade essential for melanoma but not lung
cancer cell survival. Secalonic acid D, known to have activity
as a kinase inhibitor, was the hit with the broadest activity6 Journal of Biomedicine and Biotechnology
(a) (b)
(c) (d)
Figure 3: GFP expression requires de novo transcription. (a) Cells treated with 200nM TSA express GFP. (b) When transcription inhibitor
actinomycin-D (0.5µg/mL) is added to LDR cells together with TSA, no GFP expression is observed. The same pattern is seen with 25nM
depsipeptide, with and without actinomycin-D in (c) and (d), respectively.
B01 S1 B12 S1
(a)
(b)
Figure 4: Transgenic LDR cells used in a low-throughput drug screen. (a) Highly responsive cells chosen for the assay were expanded
clonally, showing 70%–90% response to 25mM butyrate (right), as compared to vehicle treated cells (left). (b) A 96-well plate used to screen
compounds from the NCI structural diversity library was visualized after treatment with 4µM compounds in DMSO, using a Discovery 1
ﬂuorescent microscope platform and processed on the ﬂy for 2 × 2 visualization per well. Hits are easily detectable by marked increase in
ﬂuorescence. Parental untransfected mouse mammary adenocarcinoma cells were used to counter screen.Journal of Biomedicine and Biotechnology 7
Table 1: Hits from the screen are diverse in their structure. Butyrate was used as a positive control. The nonautoﬂuorescent hits caused cells
to express GFP, but have unique structures.
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across all human cancer lines tested. To evaluate whether
its ability to inhibit cell viability was speciﬁc for cancer
versus normal cells, we measured its eﬀects on a pair of
matched lines derived from the lung cancer and the normal
lung epithelium from the same patient. This revealed that
secalonic acid D lacks speciﬁcity and inhibits a mechanism
common to the survival of both normal and cancer cells
(Figure 6(a)). This mechanism involves, at least in part,
blocking of cell cycle progression in G2/M of the cell cycle,
similar to the eﬀects of TSA, as can be seen in Figure 6(b).
To directly test whether LDR hits had the ability to
inhibit HDAC activity, we performed in vitro HDAC assays
in nuclear extracts, using a commercially available substrate
conjugated to a ﬂuorophore, which is cleaved only from
deacetylated substrate in an activation step. Figure 6(c)
d e m o n s t r a t e st h a ta t1 0 µM, only NSC-22206 inhibited
HDAC activity. The lack of inhibition by NSC-22225 was
surprising, leading us to conﬁrm that the activity of NSC-
22206 was speciﬁc and not the result of inhibition of
the coupled activator reaction used in this assay. NSC-
22206 did not aﬀect the coupled reaction and was eﬀective
in inhibiting puriﬁed HDAC1 (Figure 6(c)) and in partly
inhibiting HDAC8 (data not shown). In terms of the HDAC
inhibition by NSC-22206, it must be concluded that its metal8 Journal of Biomedicine and Biotechnology
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Figure 5: Characterization of assay hits. Dose-response experiments were performed with secalonic acid D, or NSC-159631 (a) and NSC-
22225 (b), a related molecule NSC-22206 (c), which diﬀers from NSC-22225 only by the metal salt (Cd for NSC-22225 and Hg for NSC-
22206). In all three cases, GFP expression was dose dependent.
salt,mercury,butnotthemetalsaltofNSC-22225,cadmium,
contributes to the inhibition, potentially by replacing zinc
in the HDAC catalytic site or by unspeciﬁcally binding
cysteine thiols [35]. Indeed, 10µM mercury chloride on
its own also inhibited HDAC activity in vitro although no
GFP induction was seen in LDR cells (data not shown).
To conﬁrm the relevance of HDAC inhibition by NSC-
22206 in vivo, we treated human lung cancer cells with this
compound as well as with TSA as a positive control and
secalonic acid as a negative control. Consistent with the
HDAC activity data, cells treated with either 200nM TSA
or 10µM NSC-22206 showed increased levels of acetylated
histone3andnochangesinmethylatedhistones(Figure 6(d)
andSupplementaryFigure2B).Incontrast,0.5µMsecalonic
acid D, which inhibited cancer cell viability, had no eﬀect on
histone acetylation, yet surprisingly it did aﬀect the global
levels of histone 3 methylation in the same experiment
(Supplementary Figure 2B) . This suggests that the ability of
secalonic acid D to kill cells may be related to its cell cycle
eﬀects as mentioned above in combination with its global
eﬀects on histone methylation. In contrast, the eﬀects of
NSC-22206 on global histone acetylation are not suﬃcient
to inhibit the viability of cancer cells. The possibility that in
combinationwithothercompoundsourhitsmaybeselective
against cancer remains open to further investigation.
4. Conclusions
We have developed a cell-based system to identify com-
pounds that potentially could aﬀect a broad spectrum
of epigenetic targets. Using this LDR assay to screen the
NCI’s structural diversity library, we have found four new
epigenetic chemical modulators whose structure varies from
known compounds in this class. Mechanistically, each smallJournal of Biomedicine and Biotechnology 9
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Figure 6: Characterization of LDR assay hits. (a) MTS Assay was performed with increasing doses of Secalonic acid D on a matched pair
of lung cells: the lung cancer line HCC4017 and the normal line HBEC30KT. Secalonic acid D did not show selectivity for cancer. (b) Cells
were treated with vehicle or drug and sorted by cell-cycle phase after propidium iodide staining. TSA (200nM) and NSC-15931 (5µM) both
caused cells to accumulate in G2/M phase as compared to vehicle or 5-azadeoxycytidine (1µM). Values do not add to 100% because of the
small fraction of sub G0/G1 cells. (c) In vitro HDAC activity assays were performed on nuclear extracts treated with 10uM hit compounds
(left panel). Puriﬁed active HDAC1 activity was assayed in the presence of increasing concentrations of NSC-22206, which inhibited HDAC1
(right panel) but did not inhibit the coupled reaction (right side of panel).” (d) H358 lung cancer cells were treated with drugs for 24h and
analyzed by Western Blot for changes in global histone modiﬁcations. NSC-22206 (10µM) and TSA (200nM) both caused an increase in
levels of acetylated histone 3 whereas NSC-159631 (0.5µM) did not.10 Journal of Biomedicine and Biotechnology
Table 2: Characterization of the anticancer properties of hits. Cell
viability assays were performed with hits from the assay, and IC50
values were obtained for several nonsmall cell lung cancer cell lines
and several melanoma cell lines (bold).
Drug ID Cell Line IC50(µM)
NSC-22225/NSC-22206
H1395 >20
H1437 >10
H358 >10
Mel270 >5
OCM3 >5
NSC-150117
H1395 2.3
H1437 >10
H358 1.9
Mel270 1.7
OCM1 3.4
OCM3 2.2
Omm1 0.5
Omm2.3 1.7
NSC-693322
H1395 >10
H1437 >10
H358 8.7
Mel270 1.5
Mel285 1.7
OCM1 1.4
OCM3 2.9
Omm1 0.1
Omm2.3 0.3
NSC-159631
H1395 0.4
H1437 0.7
H358 0.6
HCC4018 0.4
Mel270 0.5
Mel285 0.8
OCM1 0.7
OCM3 0.3
Omm2.3 0.5
molecule hit exhibits unique properties in their ability to
block cell cycle progression, inhibit HDACs, alter global
histone acetylation, and induce cancer cell death. These
chemical modulators may now be explored to deﬁne their
speciﬁc molecular targets and to identify further their anti-
cancer applications alone or in combination with existing
anticancer drugs.
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